Drug Trial Radar · NCT07058077
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
153
Planned (sponsor's estimate)
Start
Aug 21, 2025
Primary completion
Dec 4, 2033
Study completion Jan 23, 2037
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to learn if enlicitide decanoate is safe and effective to treat children and adolescents with heterozygous familial hypercholesterolemia (HeFH) and high amounts of low-density lipoprotein cholesterol (LDL-C) in the blood. The goals of this study are to learn about the safety of enlicitide and if children tolerate it, what happens to enlicitide in a child's body over time, and if enlicitide works to lower cholesterol levels in children more than a placebo.
Conditions
- Heterozygous Familial Hypercholesterolemia (HeFH)
Interventions
Enlicitide DecanoateDrug
Enlicitide decanoate taken by mouth
PlaceboDrug
Placebo tablet matched to enlicitide decanoate taken by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Maximum Plasma Concentration (Cmax) of EnlicitideTime frame: At designated timepoints (up to 24 hours postdose on day 14)
- Part A: Area Under the Concentration-Time Curve from 0 to 24 Hours (AUC0-24) of EnlicitideTime frame: At designated timepoints (up to 24 hours postdose on day 14)
- Part B: Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)Time frame: Baseline and Week 24
- Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 188 weeks
- Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 180 weeks
Locations
50 sites in 20 countries. Site status is shown where the registry gives one.
Nemours/Alfred I. duPont Hospital for Children ( Site 0001)
Wilmington, Delaware · Recruiting
Children's National Medical Center ( Site 0015)
Washington D.C., District of Columbia · Recruiting
Excel Medical Clinical Trials ( Site 0008)
Boca Raton, Florida · Recruiting
Children's Healthcare of Atlanta Cardiology ( Site 0026)
Atlanta, Georgia · Recruiting
Boston Children's Hospital ( Site 0018)
Boston, Massachusetts · Recruiting
St. Louis Children's Hospital ( Site 0014)
St Louis, Missouri · Recruiting
Cincinnati Children's Hospital Medical Center ( Site 0016)
Cincinnati, Ohio · Recruiting
West Virginia University ( Site 0013)
Morgantown, West Virginia · Recruiting
Monash Children s Hospital ( Site 1603)
Clayton, Victoria, Australia · Recruiting
Perth Children s Hospital ( Site 1601)
Nedlands, Western Australia, Australia · Recruiting
UZ Antwerpen ( Site 0601)
Edegem, Antwerpen, Belgium · Recruiting
Instituto Dante Pazzanese de Cardiology ( Site 0206)
São Paulo, Brazil · Recruiting
Incor - Instituto do Coracao ( Site 0200)
São Paulo, Brazil · Recruiting
Universidade Federal Do Ceara ( Site 0201)
Fortaleza, Ceará, Brazil · Recruiting
Hospital Dr. Hernan Henriquez Aravena ( Site 0301)
Temuco, Araucania, Chile · Recruiting
Biocenter ( Site 0305)
Concepción, Biobio, Chile · Recruiting
Explora Salud ( Site 0304)
Santiago, Region M. de Santiago, Chile · Recruiting
Pontificia Universidad Catolica de Chile ( Site 0300)
Santiago, Region M. de Santiago, Chile · Recruiting
Children's Hospital Capital Institute of Pediatrics ( Site 1908)
Beijing, Beijing Municipality, China · Recruiting
Beijing Anzhen Hospital. Capital Medical University ( Site 1917)
Beijing, Beijing Municipality, China · Recruiting
Guangdong Provincial People's Hospital ( Site 1915)
Guangzhou, Guangdong, China · Recruiting
Children's Hospital of Fudan University ( Site 1906)
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Children's Medical Center ( Site 1918)
Shanghai, Shanghai Municipality, China · Recruiting
The Children's Hospital of Zhejiang University School of Medicine ( Site 1905)
Hangzhou, Zhejiang, China · Recruiting
Clinica de la Costa S.A.S. ( Site 0400)
Barranquilla, Atlántico, Colombia · Recruiting
Oncomédica S.A.S ( Site 0401)
Montería, Departamento de Córdoba, Colombia · Recruiting
Fundación Cardiovascular de Colombia ( Site 0402)
Piedecuesta, Santander Department, Colombia · Recruiting
Fundacion Valle del Lili ( Site 0403)
Cali, Valle del Cauca Department, Colombia · Recruiting
Fakultni nemocnice v Motole ( Site 0700)
Prague, Czechia · Recruiting
Detska nemocnice FN Brno ( Site 0701)
Brno, Brno-mesto, Czechia · Recruiting
Vseobecna fakultni nemocnice v Praze ( Site 0702)
Prague, Praha 2, Czechia · Recruiting
New Childrens Hospital ( Site 0800)
Helsinki, Uusimaa, Finland · Recruiting
Hopital Femme Mere Enfant ( Site 2101)
Bron, Rhone, France · Recruiting
Universitaetsklinikum Freiburg ( Site 2203)
Freiburg im Breisgau, Baden-Wurttemberg, Germany · Recruiting
Chutoen General Medical Center ( Site 2003)
Kakegawa, Shizuoka, Japan · Recruiting
INVECORDIS S.C. ( Site 0503)
Huixquilucan, Mexico · Recruiting
Laboratorio de Patología Clínica del Hospital Universitario "Dr. José Eleuterio González" ( Site 0501)
Monterrey, Nuevo León, Mexico · Recruiting
Centro de Investigacion Clinica de Oaxaca ( Site 0505)
Oaxaca City, Oaxaca, Mexico · Recruiting
Amsterdam UMC, locatie AMC ( Site 1000)
Amsterdam, North Holland, Netherlands · Recruiting
New Zealand Clinical Research (Christchurch) ( Site 1700)
Christchurch, Canterbury, New Zealand · Recruiting
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.